National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix C: The Burden of Disease Resulting from Diarrhea." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
160
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

TABLE C.1 Annual Incidence of Diarrheal Diseasea (episodes per individual per year)

 

Age Group (years)

Region

Under 2b

2–4b

Under 5

5–14

15–59

60 and Over

Africa

7.0

3.0

5

1

0.3

0.3

Asia

5.25

1.5

3

0.5

0.2

0.2

Latin America

6.0

2.0

4

1

0.25

0.25

Oceania

3.5

1.0

2

0.5

0.2

0.2

More developed countries

1–2

0.5

0.5

0.1

0.1

0.1

aModified from Programme for Control of Diarrhoeal Diseases (1984).

bUnder 5 years episodes are estimated to be distributed 0.7:0.3 between under 2 years and 2 to 4 years age groups.

TABLE C.2 Estimated 1984 Population for Regions Where Developing Countries Predominatea (thousands)

 

Age Group (years)

 

Region

Under 5

5–14

15–59

60 and Over

Total

Africa

96,802

141,459

265,451

27,288

531,000

Asia

343,700

666,402

1,472,242

179,656

2,662,000

Latin America

57,235

100,220

214,415

25,130

397,000

Oceania

822

1,285

2,620

273

5,000

Total

498,559

909,366

1,954,728

232,347

3,595,000

aDerived by applying the proportions of the 1980 population in various age groups to the mid-1984 population projections. See Chapter 4, Table 4.4, for the countries included.

million deaths). This total reasonably agrees with the estimated 3.5 million derived by the foregoing approach.

Tables C.6 and C.7 show the estimated distribution of the diarrheal disease burden by etiology. These estimates were derived from expert judgment after a review of available publications and from personal field experience. Only those etiologies for which vaccine prospects are reasonably promising were considered. Salmonella was subsequently dropped from consideration.

Page
160
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)